Patient Case: A 76-Year-Old Woman with ROS1+ Metastatic NSCLC

Data from a phase 1a/1b trial show that no patients discontinued STK-012 due to treatment-related adverse effects.

Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

Phase 2 data showed no dose-limiting toxicities with EIK1001 plus pembrolizumab in patients with advanced non–small cell lung cancer.

Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Improvements in safety were observed without compromising efficacy after non-myeloablative lymphodepletion was reduced in this NSCLC population.

Data from the phase 2 TUXEDO-3 trial support patritumab deruxtecan as a novel treatment option across different cancer populations with brain metastases.